×

Sign In

Search
Home

Skye Bioscience’s obesity drug fails to meet main goal of mid-stage study

By Thomson Reuters Oct 6, 2025 | 6:09 AM

(Reuters) -Skye Bioscience said on Monday its experimental obesity drug did not meet the main goal of a mid-stage study.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar)

Tobacco industry links with EU officials underreported, campaigners say

Judge rejects US bid to toss California high-speed rail lawsuit

UAE digital lender Wio Bank bets on payments, wealth to power next growth phase

Bezos' Blue Origin working on orbital data center technology, WSJ reports

Mavs C Dereck Lively II to have season-ending foot surgery

Canada lists four extremist, insurgent groups as foreign terrorist entities

Privacy Policy
Terms Of Service

Copyright © 2025. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.